Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
GeekWire
July 18, 2024
Media
“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”
“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”